IS4979A - Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF) - Google Patents

Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF)

Info

Publication number
IS4979A
IS4979A IS4979A IS4979A IS4979A IS 4979 A IS4979 A IS 4979A IS 4979 A IS4979 A IS 4979A IS 4979 A IS4979 A IS 4979A IS 4979 A IS4979 A IS 4979A
Authority
IS
Iceland
Prior art keywords
laxatives
pde
tnf
production
necrosis factor
Prior art date
Application number
IS4979A
Other languages
English (en)
Inventor
Marfat Anthony
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS4979A publication Critical patent/IS4979A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS4979A 1996-09-04 1999-02-16 Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF) IS4979A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2544696P 1996-09-04 1996-09-04
PCT/IB1997/001023 WO1998009961A1 (en) 1996-09-04 1997-08-25 Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)

Publications (1)

Publication Number Publication Date
IS4979A true IS4979A (is) 1999-02-16

Family

ID=21826124

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4979A IS4979A (is) 1996-09-04 1999-02-16 Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF)

Country Status (35)

Country Link
US (1) US6262040B1 (is)
EP (1) EP0931075A1 (is)
JP (2) JP3554337B2 (is)
KR (1) KR100338610B1 (is)
CN (1) CN1234031A (is)
AP (1) AP795A (is)
AR (1) AR008162A1 (is)
AU (1) AU724549B2 (is)
BG (1) BG64447B1 (is)
BR (1) BR9712005A (is)
CA (1) CA2264798A1 (is)
CO (1) CO4600636A1 (is)
DZ (1) DZ2303A1 (is)
EA (1) EA002113B1 (is)
GT (1) GT199700102A (is)
HN (1) HN1997000126A (is)
HR (1) HRP970478B1 (is)
HU (1) HUP9903248A3 (is)
ID (1) ID18157A (is)
IL (1) IL128642A0 (is)
IS (1) IS4979A (is)
MA (1) MA26439A1 (is)
NO (1) NO991048L (is)
NZ (1) NZ334213A (is)
OA (1) OA10985A (is)
PA (1) PA8437301A1 (is)
PE (1) PE107998A1 (is)
PL (1) PL332187A1 (is)
SK (1) SK27299A3 (is)
TN (1) TNSN97148A1 (is)
TR (1) TR199900481T2 (is)
TW (1) TW402595B (is)
WO (1) WO1998009961A1 (is)
YU (1) YU11299A (is)
ZA (1) ZA977903B (is)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
TR200001234T2 (tr) * 1997-11-04 2000-08-21 Pfizer Products Inc. Terapötik aktif bileşiklerde katelkolün indazol biyoisoster değişimi.
YU25400A (sh) * 1997-11-04 2003-07-07 Pfizer Products Inc. Terapeutski aktivna jedinjenja sa indazolom
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
US6191300B1 (en) 1999-04-16 2001-02-20 Eastman Chemical Company Process for the preparation of cyclopropylacetonitrile
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
EA006685B1 (ru) 1999-08-21 2006-02-24 Алтана Фарма Аг Синергетическая композиция
WO2001047915A1 (en) * 1999-12-23 2001-07-05 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
CN1537018A (zh) * 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
EP1389468A4 (en) * 2001-05-23 2007-01-10 Tanabe Seiyaku Co COMPOSITIONS PROMOTING THE GUISON OF A BONE FRACTURE
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
MXPA04009997A (es) * 2002-04-12 2004-12-13 Celgene Corp Modulacion de la diferenciacion de celulas madre y progenitoras, ensayos y usos de las mismas.
WO2003102151A2 (en) * 2002-05-30 2003-12-11 Celgene Corporation Modulating cell differentiation and treating myeloprolifertive disorders with jnk/mkk inhibitors
JP2006504656A (ja) 2002-07-19 2006-02-09 メモリー・ファーマシューティカルズ・コーポレイション Ｎ−置換されたアニリン及びジフェニルアミンアナログを含むホスホジエステラーゼ４インヒビター
RU2354648C2 (ru) * 2002-07-19 2009-05-10 Мемори Фармасьютиклз Корпорейшн Соединения 6-амино-1н-индазола и 4-аминобензофурана в качестве ингибиторов фосфодиэстеразы 4
KR20050075430A (ko) * 2002-11-19 2005-07-20 메모리 파마슈티칼스 코포레이션 포스포디에스테라제 4 억제제
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1625121B1 (en) 2002-12-20 2010-02-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
JP2005089457A (ja) * 2003-09-03 2005-04-07 Yung Shin Pharmaceutical Industry Co Ltd 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
RU2006134022A (ru) 2004-02-27 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные индазола и содержащие их фармацевтические композиции
JP2007523936A (ja) 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー ヘテロアリール縮合ピラゾロ誘導体
BRPI0508036A (pt) 2004-02-27 2007-07-17 Hoffmann La Roche derivados fundidos de pirazola
CA2566477A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (es) 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
JP2007537238A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のためのピリミジン誘導体
CN1997626A (zh) * 2004-07-12 2007-07-11 默克公司 组蛋白脱乙酰基酶的抑制剂
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
TW200621237A (en) 2004-11-01 2006-07-01 Wyeth Corp [(1-h-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1h-indazol-3-yl)methanones
WO2006129158A2 (en) * 2005-05-30 2006-12-07 Ranbaxy Laboratories Limited 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i
KR101011956B1 (ko) 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 Ｐ３８ ｍαｐ 키나아제 저해제 및 이의 사용 방법
EP1928866A1 (en) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
NZ570846A (en) 2006-01-31 2011-08-26 Array Biopharma Inc Kinase inhibitors and methods of use thereof
US20100056791A1 (en) * 2006-09-01 2010-03-04 Yasushi Kohno Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
CA2671543A1 (en) * 2006-12-05 2008-06-12 Chung-Ming Sun Indazole compounds
MX2009009793A (es) 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
JP2012521429A (ja) * 2009-03-23 2012-09-13 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛治療用のｐ２ｘ３受容体アンタゴニスト
CN102939283B (zh) * 2010-04-22 2015-06-03 詹森药业有限公司 可用作己酮糖激酶抑制剂的吲唑化合物
JP2014511389A (ja) 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
JP2020502058A (ja) * 2016-11-18 2020-01-23 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ジアシルグリセリドｏ−アシルトランスフェラーゼ２の阻害薬として有用なインダゾール誘導体
MX2021015996A (es) 2019-07-11 2022-06-08 Escape Bio Inc Indazoles y azaindazoles como inhibidores de cinasa de repetición rica en leucina 2 (lrrk2).
CN112694474B (zh) * 2019-10-23 2022-03-18 四川大学 吲唑类衍生物及其制备方法和用途
WO2022256303A1 (en) * 2021-05-31 2022-12-08 Genscript Usa Inc. Electrografted films for dna synthesis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE531433A (is) * 1953-06-17
US4665397A (en) 1983-11-01 1987-05-12 Universal Photonics, Inc. Apparatus and method for a universal electronic locking system
GB8524157D0 (en) * 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
JPH061350B2 (ja) * 1985-07-26 1994-01-05 コニカ株式会社 ハロゲン化銀写真感光材料
JPS6250751A (ja) * 1985-08-29 1987-03-05 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
GB8609175D0 (en) * 1986-04-15 1986-05-21 Ici America Inc Heterocyclic carboxamides
ES2095855T3 (es) * 1989-02-02 1997-03-01 Yamanouchi Pharma Co Ltd Derivados de tetrahidrobencimidazol.
DK0527736T3 (da) * 1990-05-18 1997-10-20 Hoechst Ag Isoxazol-4-carboxylsyreamider og hydroxyalkyliden-cyanoacetamider, lægemidler indeholdende disse forbindelser og anvendelsen af disse lægemidler.
US5444038A (en) 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
RU2131876C1 (ru) * 1993-07-06 1999-06-20 Пфайзер Инк. Бициклические тетрагидропиразолпиридины или их фармацевтически приемлемые соли, фармацевтическая композиция, способ ингибирования фосфодиэстеразы, способ лечения
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
DE69508568T2 (de) 1994-02-17 1999-10-21 American Home Prod Substituierte biphenyl-derivate mit phosphodiesterase inhibierender wirkung
WO1995027692A1 (en) 1994-04-08 1995-10-19 Smithkline Beecham Corporation Subtituted biphenyl tnf inhibitors
JPH08143525A (ja) * 1994-11-21 1996-06-04 Banyu Pharmaceut Co Ltd ヒドロキシ安息香酸アミド誘導体を有効成分とする骨疾患の予防・治療剤
DK0912558T3 (da) * 1996-06-25 2003-08-18 Pfizer Substituerede indazolderivater og deres anvendelse som inhibitorer af phosphodiesterase (PDE) type IV og tumornekrosefaktor (TNF)
ATE211740T1 (de) * 1996-06-27 2002-01-15 Pfizer Substituierte indazolderivate

Also Published As

Publication number Publication date
AR008162A1 (es) 1999-12-09
IL128642A0 (en) 2000-01-31
CO4600636A1 (es) 1998-05-08
EA199900183A1 (ru) 1999-08-26
MA26439A1 (fr) 2004-12-20
GT199700102A (es) 1999-02-25
BR9712005A (pt) 1999-08-24
CN1234031A (zh) 1999-11-03
EA002113B1 (ru) 2001-12-24
AU3781397A (en) 1998-03-26
JP2004217668A (ja) 2004-08-05
CA2264798A1 (en) 1998-03-12
WO1998009961A1 (en) 1998-03-12
KR20000068421A (ko) 2000-11-25
TR199900481T2 (xx) 1999-06-21
DZ2303A1 (fr) 2002-12-28
HRP970478B1 (en) 2002-10-31
HN1997000126A (es) 1997-12-26
HUP9903248A2 (hu) 2000-04-28
SK27299A3 (en) 2000-10-09
AP9701080A0 (en) 1997-10-31
OA10985A (en) 2001-11-01
JP3554337B2 (ja) 2004-08-18
BG64447B1 (en) 2005-02-28
ZA977903B (en) 1999-03-03
EP0931075A1 (en) 1999-07-28
NO991048L (no) 1999-05-03
AP795A (en) 1999-12-28
NO991048D0 (no) 1999-03-03
PE107998A1 (es) 1999-01-30
NZ334213A (en) 2000-08-25
KR100338610B1 (ko) 2002-05-27
JP2000502724A (ja) 2000-03-07
AU724549B2 (en) 2000-09-28
PA8437301A1 (es) 1999-12-27
TW402595B (en) 2000-08-21
HRP970478A2 (en) 1998-08-31
PL332187A1 (en) 1999-08-30
US6262040B1 (en) 2001-07-17
BG103195A (en) 1999-09-30
YU11299A (sh) 2001-07-10
TNSN97148A1 (fr) 2005-03-15
ID18157A (id) 1998-03-05
HUP9903248A3 (en) 2000-07-28

Similar Documents

Publication Publication Date Title
IS4979A (is) Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF)
IS4871A (is) Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF)
IS4910A (is) Setnar indazól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerðar IV og æxlisdrepsþáttar lata
AU2001296609A1 (en) High-density metal capacitor using dual-damascene copper interconnect
EP0987263A3 (en) Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors
NO970412D0 (no) Indol-, indazol-, pyridopyrrol- og pyridopyrazol-derivater med antiastmatisk, antiallergisk, anti-inflammatorisk og immunomodulerende virkning
DE69633503D1 (de) 1,2,4- triazolo (4,3-b) pyridazinderivate und ihre verwendung
MXPA02009550A (es) Derivados de pirano (2,3,c)imidazo(1,2-a]piridina para el tratamiento de trastornos gastrointestinales.
DK0983249T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater
IS5654A (is) Aðferð til framleiðslu á pýrazóló[4,3-d]pýrimidín-7-ón-3-pýridýlsúlfónýl efnasamböndum og milliefnum af þeim
NO934227D0 (no) Pyrrolderivater, fremgangsm}te for deres fremstilling og terapeutiske anvendelse
AU5022400A (en) Tumor necrosis factor receptor 5
DE69707293D1 (de) Pyrrolo(3,2-c)chinolin-derivate
AU2001278550A1 (en) 1-(4-oxo-3,5-dihydro-4h-pyridazino(4,5-b)indole-1-carbonyl (piperazine) derivatives, their preparation and therapeutic application
AU2002249706A1 (en) Plate and tube join and method